Cambrex invests in new continuous flow technology
Investment will focus on the rapid and successful development of processes to supply clinical and commercial demand for chemical syntheses.
Cambrex has completed the installation of multiple continuous flow reactor platforms at its High Point, NC facility. The investment underpins Cambrex’s on-going commitment to new technologies and aims to reinforce the company’s existing experience in continuous flow. This latest investment in continuous flow for process development will focus on the rapid and successful development of processes to supply clinical as well as commercial demand for chemical syntheses.
The investment in developmental capabilities builds upon the recent expansions made at the commercial-scale in the dedicated continuous flow production unit, at the Karlskoga, Sweden facility, which is capable of producing multiple metric tons of high purity intermediates per annum.
The new development center at High Point will be led by Dr Shawn Conway, who has joined Cambrex as Director of Engineering R&D. With extensive experience in both pilot- and commercial-scale continuous processing, Dr Conway will be supported by a team of chemical engineers.
“We are seeing significant interest in continuous flow development and production, predominantly from established pharmaceutical companies looking for process improvements in Phase II,” commented Brian Swierenga, VP, Operations and Site Director for Cambrex High Point. He added: “We have designed the new laboratory and GMP pilot plant with maximum flexibility in mind, allowing us to explore the possibilities for both new and existing production projects, either on a FTE or custom contract basis.”
The continuous flow development center is the latest investment at Cambrex’s High Point site which has recently seen the completion and qualification of a new 11,000 sq.ft. analytical laboratory and a 400 sq.ft. pilot plant expansion with a reactor capacity of 4,000 L.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance